Special issue on recent advances in understanding the pathogenesis of alcoholic and non-alcoholic fatty liver diseases and Hepatocellular Carcinoma
Published 30 May, 2022
Introduction:
Non-alcoholic fatty liver disease (NAFLD) and alcohol-associated liver disease (ALD) are the two leading causes of end-stage liver disease, liver cancer and liver transplants. There is an unmet need for effective clinical management of these diseases. Developing novel and safe therapies requires improved understanding of the disease pathogenesis and identification of novel drug targets through basic and translational research.
For this special issue, we are looking for original research articles that advance current understanding of the disease mechanisms and novel treatment strategies. We are also looking for review articles that highlight recent advances in the field of fatty liver diseases.
Topics covered:
These will include, but not be limited to:
- Lipid metabolism in fatty liver diseases
- Alcohol in fatty liver diseases
- Cholesterol and bile acid signalling in fatty liver diseases
- Inter-organ crosstalk in fatty liver diseases
- Pathogenic mechanisms of NAFL to NASH progression
- Therapy for fatty liver diseases
Important deadlines:
- Submission deadline: 30 August 2022
- Publication date:30 September 2022
Submission instructions:
Please read the Guide for Authors before submitting. All articles should be submitted online; please select Special issue: Pathogenesis of ALD and NAFLD on submission.
Guest Editors:
- John Y. L. Chiang: Northeast Ohio Medical University, USA. Email: jchiang@neomed.edu
- Tiangang Li: University of Oklahoma Health Sciences Center, USA. Email: tiangang-li@ouhsc.edu
